Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMERALD
2018-002990-24Phase 3Completed
- Sponsor
- Stemline Therapeutics
- Start
- Mar 2019
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing Elacestrant with Standard of care endocrine monotherapy (2 arms). Primary endpoint: IRC-assessed progression-free survival in ESR1-mut subjects. Started Mar 2019; status: completed.
02
Drugs
elacestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2018-002990-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002990-24.